Enhancing radiotherapy through a greater understanding of homologous recombination

Seminars in Radiation Oncology

Volumn 20, Issue 4, 2010, Pages

  Barker, Christopher A ^a   Powell, Simon N ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; DNA; ERLOTINIB; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; IMATINIB; MITOMYCIN C; NAVELBINE; PACLITAXEL; PANOBINOSTAT; PCI 24781; PLATINUM DERIVATIVE; TANESPIMYCIN; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; BASAL CELL CARCINOMA; BLADDER CANCER; BREAST CANCER; CANCER RADIOTHERAPY; DNA DAMAGE; DNA REPAIR; DRUG MECHANISM; GENE; HEAD AND NECK CANCER; HOMOLOGOUS RECOMBINATION; HUMAN; LUNG CANCER; MENINGIOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RECTUM CANCER; REVIEW; STOMACH CANCER; THYROID CANCER; TUMOR CELL;

EID: 77956469624     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semradonc.2010.05.001     Document Type: Review

References (40)

1. Ward J.F. The yield of DNA double-Strand breaks produced intracellularly by ionizing-radiation-A review. Int J Radiat Biol 1990, 57:1141-1150.
2. Powell S.N., Kachnic L.A. Therapeutic exploitation of tumor cell defects in homologous recombination. Anti Cancer Agents Med Chem 2008, 8:448-460.
3. Filippo J.S., Sung P., Klein H. Mechanism of eukaryotic homologous recombination. Annu Review Biochem 2008, 77:229-257.
4. Szostak J.W., Orr-Weaver T.L., Rothstein R.J., et al. The double-strand-break repair model for recombination. Cell 1983, 33:25-35.
5. Farmer H., McCabe N., Lord C.J., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434:917-921.
6. Willers H., Dahm-Daphi J., Powell S.N. Repair of radiation damage to DNA. Br J Cancer 2004, 90:1297-1301.
7. Bryant H.E., Schultz N., Thomas H.D., et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434:913-917.
8. Foulkes W.D. Molecular origins of cancer: Inherited susceptibility to common cancers. N Engl J Med 2008, 359:2143-2153.
9. Hiel J.A., Weemaes C.M., van den Heuvel L.P., et al. Nijmegen breakage syndrome. Arch Dis Child 2000, 82:400-406.
10. Miyagawa K. Clinical relevance of the homologous recombination machinery in cancer therapy. Cancer Sci 2008, 99:187-194.
11. Li D., Liu H., Jiao L., et al. Significant effect of homologous recombination DNA repair gene polymorphisms on pancreatic cancer survival. Cancer Res 2006, 66:3323-3330.
12. Li D., Frazier M., Evans D.B., et al. Single nucleotide polymorphisms of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer. J Clin Oncol 2006, 24:1720-1728.
13. Barnett G.C., West C.M.L., Dunning A.M., et al. Normal tissue reactions to radiotherapy: Towards tailoring treatment dose by genotype. Nat Rev Cancer 2009, 9:134-142.
14. Liu S.K., Olive P.L., Bristow R.G. Biomarkers for DNA DSB inhibitors and radiotherapy clinical trials. Cancer Metastasis Rev 2008, 27:445-458.
15. Soderlund K., Skoog L., Fornander T., et al. The BRCA1/BRCA2/Rad51 complex is a prognostic and predictive factor in early breast cancer. Radiother Oncol 2007, 84:242-251.
16. Soderlund K., Stal O., Skoog L., et al. Intact Mre11/Rad50/Nbs1 complex predicts good response to radiotherapy in early breast cancer. Int J Radiat Oncol Biol Phys 2007, 68:50-58.
17. Yang M.H., Chiang W.C., Chou T.Y., et al. Increased NBS1 expression is a marker of aggressive head and neck cancer and overexpression of NBS1 contributes to transformation. Clin Cancer Res 2006, 12:507-515.
18. Connell P.P., Jayathilaka K., Haraf D.J., et al. Pilot study examining tumor expression of Rad51 and clinical outcomes in human head cancers. Int J Oncol 2006, 28:1113-1119.
19. Willers H., Taghian A.G., Luo C.M., et al. Utility of DNA repair protein foci for the detection of putative BRCA1 pathway defects in breast cancer biopsies. Mol Cancer Res 2009, 7:1304-1309.
20. Collis S.J., Tighe A., Scott S.D., et al. Ribozyme minigene-mediated Rad51 down-regulation increases radiosensitivity of human prostate cancer cells. Nucleic Acids Res 2001, 29:1534-1538.
21. Yu D., Sekine E., Fujimori A., et al. Downregulation of BRCA2 causes radio-sensitization of human tumor cells in vitro and in vivo. Cancer Sci 2008, 99:810-815.
22. Iliakis G., Wu W.Q., Wang M.L. DNA double strand break repair inhibition as a cause of heat radiosensitization: Re-evaluation considering backup pathways of NHEJ. Int J Hyperthermia 2008, 24:17-29.
23. Frankenberg-Schwager M., Gebauer A., Koppe C., et al. Single-Strand annealing, conservative homologous recombination, nonhomologous DNA end joining, and the cell cycle-dependent repair of DNA double-Strand breaks induced by sparsely or densely ionizing radiation. Radiat Res 2009, 171:265-273.
24. Camphausen K., Tofilon P.J. Inhibition of Hsp90: A multitarget approach to radiosensitization. Clin Cancer Res 2007, 13:4326-4330.
25. Noguchi M., Yu D., Hirayama R., et al. Inhibition of homologous recombination repair in irradiated tumor cells pretreated with Hsp90 inhibitor seventeen-allylamino-seventeen-demethoxygeldanamycin. Biochem Biophys Res Commun 2006, 351:658-663.
26. Chen G., Yuan S.S.F., Liu W., et al. Radiation-induced assembly of Rad51 and Rad52 recombination complex requires ATM and c-Abl. J Biol Chem 1999, 274:12748-12752.
27. Russell J.S., Brady K., Burgan W.E., et al. Gleevec-mediated inhibition of Rad51 expression and enhancement of tumor cell radiosensitivity. Cancer Res 2003, 63:7377-7383.
28. Bartkowiak D., Hipp P.R., Mendonca M.S., et al. A radioprotective effect of imatinib (Gleevec((R))) in human squamous carcinoma cells. Strahlenther Onkol 2007, 183:432-439.
29. Chinnaiyan P., Huang S.M., Vallabhaneni G., et al. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res 2005, 65:3328-3335.
30. Li L.P., Wang H., Yang E.S., et al. Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cells. Cancer Res 2008, 68:9141-9146.
31. Prados M.D., Chang S.M., Butowski N., et al. Phase II Study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol 2009, 27:579-584.
32. Peereboom D.M., Shepard D.R., Ahluwalia M.S., et al. Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme. J Neuro Oncol 2009.
33. Brown P.D., Krishnan S., Sarkaria J.N., et al. Phase. I/II Trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group study N0177. J Clin Oncol 2008, 26:5603-5609.
34. McBride W.H., Iwamoto K.S., Syljuasen R., et al. The role of the ubiquitin/proteasome system in cellular responses to radiation. Oncogene 2003, 22:5755-5773.
35. Murakawa Y., Sonoda E., Barber L.J., et al. Inhibitors of the proteasome suppress homologous DNA recombination in mammalian cells. Cancer Res 2007, 67:8536-8543.
36. Shi W., Ma Z.F., Willers H., et al. Disassembly of MDC1 foci is controlled by ubiquitin-proteasome-dependent degradation. J Biol Chem 2008, 283:31608-31616.
37. Berenson J.R., Yellin O., Patel R., et al. A phase I study of samarium lexidronam/bortezomib combination therapy for the treatment of relapsed or refractory multiple myeloma. Clin Cancer Res 2009, 15:1069-1075.
38. Brunner T.B., Geiger M., Grabenbauer G.G., et al. Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer. J Clin Oncol 2008, 26:2699-2706.
39. De Schutter H., Nuyts S. Radiosensitizing potential of epigenetic anticancer drugs. Anti Cancer Agents Med Chem 2009, 9:99-108.
40. Adimoolam S., Sirisawad M., Chen J., et al. HDAC inhibitor PCI-24781 decreases Rad51 expression and inhibits homologous recombination. Proc Natl Acad Sci U S A 2007, 104:19482-19487.